Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study

• DOI: 10.1007/s10096-017-2971-2
• Publication Date: 2017-04-05T08:13:00Z
• Authors: V. Prendki; T. Ferry; P. Sergent; E. Oziol; E. Forestier; T. Fraisse; S. Tounes; S. Ansart; J. Gaillat; S. Bayle; O. Ruyer; F. Borlot; G. Le Falher; B. Simorre; F.-A. Dauchy; S. Greffe; T. Bauer; E. N. Bell; B. Martha; M. Martinot; M. Froidure; M. Buisson; A. Waldner; X. Lemaire; A. Bosseray; M. Maillet; V. Charvet; A. Barrelet; B. Wyplosz; M. Noaillon; E. Denes; E. Beretti; M. Berlioz-Thibal; V. Meyssonnier; E. Fourniols; L. Tliba; A. Eden; M. Jean; C. Arvieux; K. Guignery-Kadri; C. Ronde-Oustau; Y. Hansmann; A. Belkacem; F. Bouchand; G. Gavazzi; F. Herrmann; J. Stirnemann; A. Dinh
• Keywords: Male; Prosthesis-Related Infections; Time Factors; Prosthetic Joint Infection; 610; 03 medical and health sciences; 0302 clinical medicine; info:eu-repo/classification/ddc/616; 616; 80 and over; Humans; Adverse Drug Reaction; Aged; Antimicrobial Therapy; ddc:616; Aged, 80 and over; Arthritis, Infectious; Arthritis; Infectious; Age Factors; Sinus Tract; info:eu-repo/classification/ddc/618.97; [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology; Anti-Bacterial Agents; 3. Good health; Treatment Outcome; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology; ddc:618.97; [SDV.IMM]Life Sciences [q-bio]/Immunology; Female; Fusidic Acid

During prosthetic joint infection (PJI), optimal surgical management with exchange of the device is sometimes impossible, especially in the elderly population. Thus, prolonged suppressive antibiotic therapy (PSAT) is the only option to prevent acute sepsis, but little is known about this strategy. We aimed to describe the characteristics, outcome and tolerance of PSAT in elderly patients with PJI. We performed a national cross-sectional cohort study of patients >75 years old and treated with PSAT for PJI. We evaluated the occurrence of events, which were defined as: (i) local or systemic progression of the infection (failure), (ii) death and (iii) discontinuation or switch of PSAT. A total of 136 patients were included, with a median age of 83 years [interquartile range (IQR) 81-88]. The predominant pathogen involved was Staphylococcus (62.1%) (Staphylococcus aureus in 41.7%). A single antimicrobial drug was prescribed in 96 cases (70.6%). There were 46 (33.8%) patients with an event: 25 (18%) with an adverse drug reaction leading to definitive discontinuation or switch of PSAT, 8 (5.9%) with progression of sepsis and 13 died (9.6%). Among patients under follow-up, the survival rate without an event at 2 years was 61% [95% confidence interval (CI): 51;74]. In the multivariate Cox analysis, patients with higher World Health Organization (WHO) score had an increased risk of an event [hazard ratio (HR) = 1.5, p = 0.014], whereas patients treated with beta-lactams are associated with less risk of events occurring (HR = 0.5, p = 0.048). In our cohort, PSAT could be an effective and safe option for PJI in the elderly.